Introduction {#sec1_1}
============

Immunotherapy has emerged as one of the hot topics of cancer treatment since the approval of ipilimumab in 2011, and subsequently PD-a inhibitors. There are several categories of immunotherapy: monoclonal antibodies, non-specific immunotherapies, oncolytic virus therapy, T-cell therapy, and cancer vaccines, some of which are still in the clinical trial phase \[[@B1], [@B2], [@B3], [@B4]\]. Monoclonal antibodies play a large role in the treatment of metastatic melanoma by serving as checkpoint inhibitors to promote T cell activation and upregulate T cell antitumor responses to suppress tumours. Since 2015, the US Food and Drug Administration (FDA) has approved three checkpoint inhibitor drugs for the treatment of metastatic melanoma, each inhibitor targeting different "brakes" of the T-cell activation pathway. Ipilimumab targets the cytotoxic T-lymphocyte antigen 4 (CTLA-4), while pembrolizumab and nivolumab target the programmed cell death receptor 1 (PD-1). Somatic mutations in melanoma are associated with presentation of cancer-specific antigens, and these antigens appeared to be the target for checkpoint inhibitor-reactivated immune cells \[[@B5]\]. Immunotherapy for metastatic cancer is not without its downfalls; the activated immune cells may also produce autoimmune reaction against healthy cells in different organs. Immune mediated adverse events have been reported and each immunotherapeutic drug seem to have distinctly different adverse effects, for example, gastrointestinal adverse effects are commonly reported in ipilimumab but not in pembrolizumab or nivolumab \[[@B6]\]. As immunotherapy can affect a whole range of systems in the body, it is necessary for physicians to document and report adverse events. In this case, we present one of the first reported case of pembrolizumab-induced pancytopenia and autoimmune hemolytic anemia (AIHA).

Case Report {#sec1_2}
===========

A 67-year-old male with a past medical history of chronic lymphocytic leukemia (CLL), and diagnosed BRAF negative metastatic melanoma in 2017 on pembrolizumab as first line treatment was presenting with shortness of breath. He presented to his medical oncology follow-up on his 8th cycle of the pembrolizumab with 1 week history of worsening fatigue and shortness of breath initially on exertion and then at rest. Routine laboratory investigations showed a hemoglobin of 66 g/L that morning at the end of June, which was quite a decrease from his baseline hemoglobin of 154 g/L as well as normal LDH (Fig. [1](#F1){ref-type="fig"}). The patient was sent to the emergency department to be assessed by hematology. He received a 1g dose of methylprednisone IV and red cell transfusion. Supportive management was done. Investigations showed that his absolute reticulocyte count was 12.8 × 10^−9^/L (*N* = 20--90) (Fig. [2](#F2){ref-type="fig"}). Peripheral blood film reflected normocytic anemia and no spherocytic hemolysis were seen on smear. Bone marrow biopsy found bone marrow involvement by the low-grade B-cell lymphoma and reduced and left shifted erythropoiesis, and the biopsy did not reflect red cell aplasia at the time.

Two weeks later, His hemoglobin was 83 g/L, white cell count 4.2 × 10^−9^/L (N = 4.5--11), platelets 45 × 10^−9^ L (*N* = 150--450), ANC 1.5 × 10^−9^ L (1.5--8 L) (Fig. [1](#F1){ref-type="fig"}). Due to the continued anemia, neutropenia and thrombocytopenia, the medical team decided to start him on prednisone at a dose of 1 mg/kg/day.

The hematologist suspected two components to his symptoms: PD-1 inhibitor use in the background of CLL. As a result he developed an evolving to aplastic anemia, with a component of autoimmune hemolytic anemia.

Two months after the emergency visit, he was followed up by the hematologist that noted bone marrow suppression -- which was slowing recovering given the rising reticulocyte count and hemolytic anemia; likely autoimmune given positive direct antiglobulin test (DAT) and response to prednisone.

Two weeks into his prednisone taper, there was a rise in his LDH and haptoglobin so the team extended the prednisone duration. When his prednisone taper was finished in October, his WBC was 13.3 × 10^−9^/L, hemoglobin 112 g/L, platelet 220 × 10^−9^/L, and lymphocyte 8.8 × 10^−9^/L (Fig. [1](#F1){ref-type="fig"}). He was found to have an enlarging pulmonary nodule and a referral was in put for stereotactic radiation. He continued to have weekly CBCs to monitor for anemia. He restarted on prednisone twice for a decrease in his hemoglobin as soon as tapering is attempted.

Discussion {#sec1_3}
==========

In our case report, we have a 67-year-old male with pre-existing CLL who was found to have anemia, thrombocytopenia and neutropenia after 8 cycles of pembrolizumab, an anti-PD-1 immunotherapy, for his metastatic melanoma. He was diagnosed with autoimmune hemolytic anemia (AIHA) based on positive DAT result and positive response to prednisone. Pancytopenia due to aplastic anemia was also diagnosed based on hypocellular finding on bone biopsy. After discontinuation of pembrolizumab and treatment with blood transfusion and ongoing steroids, he is responded appropriately with rising RBC and reticulocyte count.

The cause of AIHA is idiopathic for a majority of patients. Other causes include drugs, malignancy, autoimmune disorders, and infections \[[@B19]\]. The diagnostic criteria include a positive DAT, laboratory finding supporting hemolysis such as increase in serum lactate dehydrogenase (LDH), and reticulocytosis and spherocytosis on peripheral blood smears \[[@B20]\].

Acquired pancytopenia can be caused by decreased production of cells, or by pooling and destruction of cells. Production of cells can be decreased by leukemia, aplastic anemia, nutritional deficiency, bone metastasis, fulminant sepsis, and myelodysplastic syndrome. Pooling/destruction of cells can be caused by splenomegaly, paroxysmal nocturnal hemoglobinuria, or acquired hemophagocytic lymphohistiocytosis \[[@B21]\].

There have been several reported cases of drug induced AIHA or pancytopenia due to pembrolizumab since anti-CTLA-4 and anti-PD-1 immunotherapies were approved by the FDA in 2011.

To this date, pembrolizumab has three reported cases of hematologic adverse effect from the treatment of different cancers. In 2016, Nair et al. reported AIHA with pure red cell aplasia after 3 cycles of pembrolizumab for malignant melanoma; In 2017, Atwal et al. reported pancytopenia after 18 cycles of pembrolizumab. In 2018, Ogawa et al. reported exacerbation of AIHA after 1 cycle of pembrolizumab treatment for lung adenocarcinoma. In these cases, recovery from anemia was achieved with the use of a combination of steroids, IVIG, RBC transfusion, and platelet transfusion \[[@B7], [@B8], [@B9]\]. A summary of adverse effects of PD-1 inhibitors used in patients with melanoma can be found in Table [1](#T1){ref-type="table"}.

Nivolumab, the other anti-PD-1 antibody therapy, has similar reports of adverse hematologic reaction. There is a total of eleven cases to date detailing either AIHA or pancytopenia as the adverse reaction. Only 5/11 of the patients resolved their anemia or pancytopenia with steroid and transfusion, and the remaining six patients either expired from their pre-existing illness before anemia improved, or still have persistent pancytopenia with bone marrow failure. In 2017, Michot et al. described three patients who had unresolved anemia, one of which died from febrile neutropenia from abdominal sepsis \[[@B15]\]. In 2016, Palla et al. described a patient who was refractory to steroid therapy and died due to her cancer before the AIHA can be corrected \[[@B14]\]. In 2018, Tokumo et al. also described a patient who died from progression of lung cancer after onset of pancytopenia before he could resolve his pancytopenia \[[@B18]\]. A summary of adverse effects of PD-1 inhibitors used in patients with other malignancies can be seen in Table [2](#T2){ref-type="table"}.

Pembrolizumab and nivolumab are antibodies that binds to PD-1 receptors to block the PD-1 receptor pathway, a pathway that leads to the downregulation of immune reactions to tumours. As a result, anti-PD-1 antibodies will reverse T-cell suppression and induce anti-tumour responses.

It is suggested that the blockade of PD-1 will enhance the T-effector cells in tissues and tumour microenvironments \[[@B22]\]. Studies have also shown an association between the inhibition of PD-1 pathway and increase in B cell activity and cytokine level \[[@B23], [@B24]\]. Hemolysis in our case can be explained by activation of pre-existing RBC specific T-effector cells or B cells by the anti-PD-1 antibodies. In addition to peripheral origins for cytopenia (AIHA and autoimmune thrombocytopenia), Michot et al. in 2017 found bone marrow failure in 3 cases of nivolumab therapy for melanoma, suggesting a central origin for immune-related cytopenia in bone marrow suppression as well \[[@B15]\].

Our case is one of the first ever reported case of drug induced AIHA and pancytopenia due to pembrolizumab. In our patient, hemolytic anemia and aplastic anemia due to bone marrow suppression were both present, suggesting PD-1 antibodies can affect RBC counts both peripherally and centrally.

Our patient does have chronic lymphocytic leukemia, and it is possible that the cytopenia is attributed to a masked progression to CLL. However, the CLL was stable and the patient did not have signs of CLL progression prior to the initiation of pembrolizumab treatment. Lymphocytosis was present in the lab work taken at baseline and after his symptoms emerged.

Although adverse effects were noted, re-challenging with the same PD-1 inhibitor can yield different results. Khan et al. re-challenged a patient with ipilimab and nivolumab, and patient redeveloped AIHA \[[@B16]\]. Conversely, Tardy et al. re-challenged a patient with nivolumab without recurrence of AIHA \[[@B17]\]. The mechanism by which autoimmune hemolysis is activated needs further studies.

Reported hematologic toxicities are rare but they can be fatal for pembrolizumab. These reports demonstrate the potential hematologic toxicity of immunotherapy, and they call for increased monitoring for the safety of patients, and familiarity with the rescue treatment for pancytopenia and AIHA caused by PD-1 inhibitors.

Conclusion {#sec1_4}
==========

Cancer patients face greater risk of immunosuppression with standard chemotherapy treatment compared to the general population. With the advance of immunotherapy for metastatic melanoma and other malignancies, a number of immuned-related AIHA and pancytopenia have been reported with PD-1 inhibitors. Physicians should be aware of the risk of hematologic toxicity and immunosupression when they prescribe immunotherapy, and execise appropriate monitoring to optimize patient safety.
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###### 

Case reports of patients with metastatic melanoma who received PD-1 inhibitor and had adverse hematologic reaction \[[@B7], [@B8], [@B9], [@B10], [@B11], [@B12]\]

                                        Nair \[[@B7]\], 2016                                                                                                                                                                                                                                                                         Atwal \[[@B8]\], 2017                                                                                                                                                                                                                                                                        Ogawa \[[@B9]\], 2018                                                                                                                                                                       Deltombe \[[@B10]\], 2017                                                                                                                                                                                                                                          Kong \[[@B11]\], 2016                                                                                                                        Khan \[[@B12]\], 2017
  ------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diagnosis                             AIHA with pure red cell aplasia                                                                                                                                                                                                                                                              Pancytopenia                                                                                                                                                                                                                                                                                 AIHA                                                                                                                                                                                        AIHA                                                                                                                                                                                                                                                               AIHA                                                                                                                                         AIHA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Age, years/ gender                    52/F                                                                                                                                                                                                                                                                                         52/F                                                                                                                                                                                                                                                                                         82/M                                                                                                                                                                                        73/M                                                                                                                                                                                                                                                               85/M                                                                                                                                         43/F
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Pre-existing comorbidities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Hypothyroidism, chronic anemia but no hemolysis before treatment of pembrolizumab                                                                                                           Kidney transplant                                                                                                                                                                                                                                                  Severe mitral regurgitation, paroxysmal afib, hypercholesterolemia                                                                           Hyperthyroidism, smoking
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Indication for PD-1 inhibitor         Malignant melanoma with LN involvement                                                                                                                                                                                                                                                       Metastatic melanoma                                                                                                                                                                                                                                                                          lung adenocarcinoma                                                                                                                                                                         Metastatic melanoma 15mth post kidney transplant                                                                                                                                                                                                                   Metastatic melanoma                                                                                                                          Metastatic melanoma
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Cycles of PD-1 inhibitor              3 cycle of pembrolizumab                                                                                                                                                                                                                                                                     18 cycles of pembrolizumab (2 mg/kg) Q3week                                                                                                                                                                                                                                                  1 cycle of pembrolizumab (200 mg/body)                                                                                                                                                      2 cycles of nivolumab (3mg/kg) Q 4 weeks                                                                                                                                                                                                                           5 cycles of nivolumab Q 2 weeks                                                                                                              2 cycles of ipilimumab and nivolumab
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Past treatment and immuno-therapies   Local resection + LN resection, adjuvant radiation therapy, 1 month of high dose IV interferon; Local resection again; ipilimumab resulted in autoimmune hepatitis; Pembrolizumab started for bilateral pelvic lymphadenopathy                                                               2 cycles of ipilimumab, 2 doses of infliximab                                                                                                                                                                                                                                                Chemoradiation therapy                                                                                                                                                                      Prior to the nivolumab, immunosuppression was reduced. Tacrolimus was switched to everolimus (2.5 mg/day) after the dx                                                                                                                                             6 cycles of dacarbazine followed by 4 cycles of ipilimumab at 3 mg/kg Q 3 weeks before nivolumab                                             Whole brain radiation therapy before starting the immunotherapy
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Treatment                             Prednisone and IVIG                                                                                                                                                                                                                                                                          Steroids, IVIG, RBC and platelet transfusion                                                                                                                                                                                                                                                 Steroids and RBC transfusion                                                                                                                                                                Steroids                                                                                                                                                                                                                                                           Steroids and RBC transfusion                                                                                                                 First AIHA episode: RBC transfusion and steroids Second AIHA episode: steroid plus rituximab
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Clinical course                       Acute anemia occurred after 3 doses; Excellent response to glucocorticoid over slow taper over 6 weeks; When prednisone was tapered to 20 mg/day, the pure red cell aplasia flare and IVIG was given to enable the tapering of steroids; Hgb and ret count remained normal after treatment   Bone biopsy before steroid and IVIG tx showed hypo-cellular for age (20% cellularity); 6 weeks after the course of IVIG revealed normocellular bone marrow for age (40% cellularity) with erythroid predominance; Blood cell counts improved greatly, although remaining lower than normal   Admitted 17 days after first dose of pembrolizumab; Diagnosed with exacerbation of preexisting AIHA induced by pembrolizumab therapy; discharged 34 days from first dose of pembrolizumab   Presented with AIHA and acute renal failure due to kidney rejection 25 days after last dose; AIHA resolved within 1 week after steroid treatment and cessation of nivolumab; Patient kidney rejection not resolved with steroid and patient returned to dialysis   Presented with AIHA within 8weeks of nivolumab treatment; Good response to steroids. AIHA resolved in ˜2 weeks                               AIHA presented 3 weeks after last dose of therapy; Anemia improved over 2 months with treatment; Once her Hgb normalized, she was re-challenged with ipilimumab and nivolumab and developed AIHA again; Anemia improved with 4 weeks treatment of steroids and rituximab
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Outcome                               Recovery from anemia; follow-up CT showed progression of her disease with new liver metastases                                                                                                                                                                                               Recovered from anemia 6 weeks later; Blood cell counts still lower than normal but doing fairly well at time of writing                                                                                                                                                                      Recovery from anemia. 33 days after discharge patient died from bacterial pneumonia                                                                                                         Recovery from anemia Patient died from melanoma dissemination 3 months later                                                                                                                                                                                       Recovery from anemia                                                                                                                         Recovery from anemia
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Caveats/ other causes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Patient had positive DAT in 2011 and negative DAT in 2012 before starting nivolumab; Not history of hemolysis nor other autoimmune disease   

###### 

Case reports of patients with other malignancies who received PD-1 inhibitor and had adverse he-matologic reaction \[[@B13], [@B14], [@B15], [@B16]\]

                                        Yuki \[[@B13]\], 2017                                                                                                                                                                                   Palla \[[@B14]\], 2016                                                                                                                                        Michot \[[@B15]\], 2017[\*](#T2F1){ref-type="table-fn"}                                                                                                                                     Michot \[[@B15]\], 2017[\*](#T2F1){ref-type="table-fn"}                                                                                                                                                     Michot \[[@B15]\], 2017[\*](#T2F1){ref-type="table-fn"}                                                                                                                                        Schwab \[[@B16]\], 2017
  ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diagnosis                             Pure red cell aplasia                                                                                                                                                                                   AIHA                                                                                                                                                          Pancytopenia/ Immune related aplastic anemia                                                                                                                                                Pancytopenia/ Immune related aplastic anemia                                                                                                                                                                Pancytopenia/ Immune related aplastic anemia                                                                                                                                                   AIHA
  Age, years/ gender                    70/F                                                                                                                                                                                                    70/M                                                                                                                                                          73/F                                                                                                                                                                                        70/M                                                                                                                                                                                                        78/M                                                                                                                                                                                           82/M
  Pre-existing comorbidities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Patient had known history of bone mets                                                                                                                                                         B-CLL, arterial HTN and prostate cancer treated with radical prostatectomy
  Indication for PD-1 inhibitor         Cardiac metastatic melanoma                                                                                                                                                                             Metastatic lung cancer                                                                                                                                        Lung adenocarcinoma                                                                                                                                                                         Lung adenocarcinoma                                                                                                                                                                                         Lung adenocarcinoma                                                                                                                                                                            Metastatic SCC of skin
  Cycles of PD-1 inhibitor              31 cycles of nivolumab (2 mg/kg) Q3 week                                                                                                                                                                2 cycles of nivolumab (3 mg/kg)                                                                                                                               12 cycles of nivolumab (3 mg/kg) Q 2 week                                                                                                                                                   10 cycles of nivolumab (3 mg/kg) Q 2 week                                                                                                                                                                   1 cycle of nivolumab (3 mg/kg) Q 2 week                                                                                                                                                        8 cycles of nivolumab (3 mg/kg) Q2 week
  Past treatment and immuno-therapies   8 cycles of dacarbazine, nimustine, vincristine, interferon B; Stereotactic radiotherapy                                                                                                                3 cycles of carboplatin and pemetrexed                                                                                                                        Thoracic radiation, carboplatin-paclitaxel, carboplatin-pemetrexed                                                                                                                          Cisplatin-pemetrexed-bevacizumab; atezolizumab; docetaxel                                                                                                                                                   Thoracic radiation, carboplatin-paclitaxel                                                                                                                                                     1st: rituximab, fludarabine, cyclophosphamide for 4 cycles; 2nd: ibrutinib for progression of B-CLL; 3rd: radiochemotherapy cisplatin 20 mg/m2 days 1--5 and radiation with 60 Gy) ×3 cycle. 4th: cetuximab and docetaxel
  Treatment                             steroids and RBC transfusion                                                                                                                                                                            Steroids and RBC transfusion                                                                                                                                  RBC and platelet transfusions; IVIG, Abx                                                                                                                                                    RBC and platelet transfusion; Granulocyte colony-stimulating factor, steroids                                                                                                                               Steroids, IVIG, GCF, Abx, RBC and platelet transfusions                                                                                                                                        Steroids
  Clinical course                       31 cycles later, hospitalized for severe anemia and cardiac failure; Anemia responsive to steroids; cardiac failure caused by severe anemia was improved with blood transfusions; Anemia was resolved   Admitted 3 days after second dose; Dx of AIHA was made; Patient was refractory to the steroid therapy and died due to resp failure                            Pancytopenia/ aplastic anemia presented after 6.2 months from first nivolumab treatment; No response to IVIG. Bone marrow failure protracted; Died 1 month after from febrile neutropenia   Pancytopenia/aplastic anemia presented after 5.4 months from first nivolumab treatment; Transient response to steroids. Bone marrow failure protracted; Persistent pancytopenia still ongoing at 4 months   Pancytopenia/ aplastic anemia occurred 0.5 month after first nivolumab treatment; No response to steroids or IVIG; Bone marrow failure; No resolution of anemia. Died 3 month after from ACS   Hemolysis stopped and peripheral blood count stabilized after 2 weeks of terminating nivolumab and treating with prednisolone
  Outcome                               Recovery from anemia; No recurrence of anemia; Good quality of life one year after cessation of nivolumab and CT showed only mild enlargement of cardiac metastasis for her melanoma                    Unresolved anemia Patient continues to have problem with afib, later develop significant resp distress; Did not want to be intubated and eventually expired   Unresolved pancytopenia. patient died 1 month later from febrile neutropenia associated with abdominal sepsis                                                                               Persistent pancytopenia still ongoing at 4 months                                                                                                                                                           Patient died 3 months later from acute coronary syndrome without resolution of aplastic anemia                                                                                                 Recovery from anemia; No signs of tumor progression
  Caveats/ other causes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              CLL
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